Cell Communication in Antiestrogen Resistance
Abstract
More women die from the estrogen receptor positive (ER+) breast cancer subtype than from any other. The proportion of early ER+ recurrences (=5 years since diagnosis) approaches that for all triple-negative breast cancers alone. Late recurrences (>5 years after diagnosis), the result of dormancy, are most common in ER+ disease and can arise decades after the initial diagnosis. Since recurrent breast cancers have escaped the effects of endocrine therapies, and are lethal, we will study endocrine resistance(Tamoxifen; Fulvestrant). Our primary objective is to identify what drives breast cancer growth and determine how to stop it. We will learn about why some breast cancers are aggressive and others are indolent, and why/how some breast cancers lay dormant for years and then re-emerge.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1191069
Entities
People
- Robert Clarke
- Yue Wang
Organizations
- University of Minnesota